Abstract
Cryptococcal infections burden the immunocompromised population with unacceptably high morbidity and mortality. This population includes HIV-infected individuals and those undergoing organ transplants, as well as seemingly immunocompetent patients (non-HIV, non-transplant). These groups are difficult to manage with the current therapeutic options and strategies, particularly in resource-limited settings. New trials aimed at providing the best treatment strategies for resource-limited countries that will reduce costs and adverse reactions have focused on decreasing the length of therapy and using more readily accessible antifungal agents such as fluconazole. Furthermore, the emergence of antifungal resistance poses another challenge for successful treatment and may require the development of new agents for improved management. This review will discuss the principles of management, current and future antifungal agents, as well as emerging techniques and future directions of care for this deadly infection.
Highlights
Cryptococcus spp. are encapsulated, polysaccharide-coated yeasts with two major species (C. neoformans and C. gattii) known to cause disease in humans
The increasing number of transplant recipients and patients receiving immunosuppressive medications such as corticosteroids, new biological drugs and new anti-neoplastic therapies has created an at-risk population with a high incidence of cryptococcal infection [2]. Antifungal drugs such as polyenes, flucytosine (5-FC), triazoles, and their combinations are the gold standard of care for cryptococcal meningitis [3]
Systemic corticosteroid use is a potentially life-saving intervention to be considered for the management of Immune Reconstitution Inflammatory Syndrome (IRIS) in cryptococcal meningitis, with a dose taper over 2–6 weeks [3]
Summary
Cryptococcus spp. are encapsulated, polysaccharide-coated yeasts with two major species (C. neoformans and C. gattii) known to cause disease in humans. These Cryptococcus spp. can invade the central nervous system (CNS) causing fungal meningoencephalitis. Mortality associated with cryptococcal meningitis is unacceptably high in both developed and developing countries. The increasing number of transplant recipients and patients receiving immunosuppressive medications such as corticosteroids, new biological drugs and new anti-neoplastic therapies has created an at-risk population with a high incidence of cryptococcal infection [2]. Antifungal drugs such as polyenes, flucytosine (5-FC), triazoles, and their combinations are the gold standard of care for cryptococcal meningitis [3]. This review will discuss the important drugs, their strategies for application, and future directions of care for this deadly infection
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
